Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Rhea-AI Summary

Silexion Therapeutics (NASDAQ:SLXN) said company management will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025 from 2:30–2:55pm ET at Florida Atlantic University Conference Center, Boca Raton, FL (Presentation Room 5).

Speakers include Ilan Hadar, CEO and Mirit Horenshtein-Hadar, CFO. Management will be available for one-on-one meetings by arrangement. A replay will be posted to Silexion's investor relations Events & Presentations page after the conference.

Argus Nov 26 session

+20.42% close to close Open Argus

Details

News Market Reaction – SLXN

On Nov 26, the day this news came out, SLXN closed 20.42% above the previous close.

Data tracked by StockTitan Argus for the Nov 26 session.

Market Context

On Nov 26, the day this news came out, the stock closed 20.4% above the previous close. A strong pos...

Analysis

On Nov 26, the day this news came out, the stock closed 20.4% above the previous close. A strong positive reaction aligns with SLXN’s history of sizable moves around communications and milestones, as seen after past updates with moves like +20.42% and +7.62%. This conference news mainly increases visibility rather than changing fundamentals, while the stock still trades far below its $63.45 52‑week high and under the $9.82 200‑day MA. Investors have also faced overhang from an effective resale S‑3 that could enable additional share supply.

Key Figures

Conference date: December 3, 2025 Presentation time: 2:30–2:55pm ET Phase 2a trial: Phase 2a +1 more

Conference date

December 3, 2025

Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Presentation time

2:30–2:55pm ET

Scheduled company presentation slot at NobleCon21

Phase 2a trial

Phase 2a

Prior clinical trial of first‑generation product in solid tumors with mutated KRAS

Conference edition

21st

Noble Capital Markets Emerging Growth Equity Conference (NobleCon21)

Historical Context

5 past events · Latest: Dec 02

5 events

1. Dec 02

   Clinical design feedback

   24h Move

   -7.6%

   German authority validated key elements of planned Phase 2/3 SIL204 trial.

2. Nov 26

   Conference appearance

   24h Move

   +20.4%

   Announcement of NobleCon21 presentation and availability for investor meetings.

3. Nov 25

   Preclinical toxicology

   24h Move

   +7.6%

   Two‑species toxicology studies for SIL204 showed no systemic organ toxicity.

4. Nov 12

   Earnings and update

   24h Move

   +3.6%

   Q3 results, increased cash, CRO selection, and progress toward Phase 2/3 start.

5. Sep 30

   Preclinical efficacy data

   24h Move

   +0.3%

   SIL204 showed up to 99.7% inhibition across multiple KRAS‑driven cancer lines.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2a clinical trial, oncology-focused biotechnology company, solid tumor cancers, kras oncogene

4 terms

phase 2a clinical trial medical

"The Company conducted a Phase 2a clinical trial in its first-generation product..."

A phase 2a clinical trial is an early-stage human study that tests a medical treatment in a small group of patients to learn whether it appears to work, to refine the right dose, and to monitor short-term safety. Investors watch these trials like prototype test drives: positive results reduce uncertainty about a drug’s chances, help estimate remaining development time and cost, and often trigger valuation changes or partnership interest in a drug program.

oncology-focused biotechnology company medical

"a clinical-stage, oncology-focused biotechnology company, today announced..."

A company that researches and develops medicines or treatments specifically for cancer and related disorders. For investors, such firms are like specialized designers: their value hinges on scientific breakthroughs, clinical trial progress, regulatory approvals, and potential market demand for a successful therapy, making them higher-risk but potentially high-reward bets compared with diversified drugmakers.

solid tumor cancers medical

"treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS..."

Solid tumor cancers are abnormal growths that form a mass in organs or tissues — like a lump in the lung, liver, breast or colon — as opposed to cancers that circulate in the blood. Investors watch them because treatments, trial results and approvals for drugs or devices targeting these tumors can drive large changes in a company’s revenue and valuation, much like a new technology that unlocks a big market.

kras oncogene medical

"cancers which have the mutated KRAS oncogene, generally considered to be the most common..."

KRAS oncogene is a gene that, when mutated, can drive cells to grow uncontrollably and form tumors; think of it as a car’s accelerator stuck in the “on” position. Investors care because KRAS mutations create clear targets for drugs, diagnostics, and clinical trials, shaping the market value of therapies and diagnostics, regulatory outcomes, and the outlook for companies developing treatments that can block or detect these mutations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21^st Annual Emerging Growth Equity Conference (NobleCon21).

Presentation details:
Type: Company presentation
Date: December 3, 2025
Time: 2:30 – 2:55pm ET
Speakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial Officer
Location: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5.

Silexion’s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

Following the conference, a replay of the presentation will be posted to SIlexion’s investor relations website’s events and presentations page available using the following link: https://silexion.com/presentations/

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Contacts:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

Chuck Padala 
LifeSci Advisors 
Chuck@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Silexion (SLXN) present at NobleCon21?

Silexion will present on December 3, 2025 from 2:30–2:55pm ET.

Who will speak for Silexion (SLXN) at NobleCon21?

Speakers are Ilan Hadar, CEO, and Mirit Horenshtein-Hadar, CFO.

Where is Silexion's (SLXN) NobleCon21 presentation located?

The presentation is at Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5.

Will Silexion (SLXN) make the presentation available after NobleCon21?

Yes. A replay will be posted to Silexion's investor relations Events & Presentations page after the conference.

How can investors arrange one-on-one meetings with Silexion (SLXN) at NobleCon21?

Interested parties should contact their conference representative to arrange one-on-one meetings with management.

Where can I find more information about Silexion Therapeutics (SLXN)?

Company information and the presentation replay will be available at https://silexion.com/presentations/ and the company website.